SAN JOSE, Calif., Feb. 4, 2019 /PRNewswire/ -- BioPharmX
Corporation (NYSE American: BPMX), a specialty pharmaceutical
company focused on developing innovative medical dermatology
products, today announced the appointment of veteran pharmaceutical
developer R. Todd Plott, M.D., as an
independent director.
Dr. Plott is a board-certified dermatologist with 30 years of
experience; 16 years of which were spent working as a
research physician with the pharmaceutical industry. He has been
involved in nine prescription drug development programs that
received approvals from the U.S. Food and Drug Administration and
other agencies. He personally led and supervised five of these
programs from initiation through approval. Dr. Plott has built and
led the development and regulatory teams that have produced some of
the most successful products in medical dermatology including, but
not limited to, SOLODYN™, an extended-release minocycline HCl
tablet for the treatment of inflammatory lesions of acne vulgaris,
ZIANA™, a clindamycin phosphate and tretinoin combination gel for
the treatment of acne vulgaris, VANOS™, a fluocinonide cream for
the treatment of psoriasis, and NORITATE™, a metronidazole cream
for the treatment of rosacea.
Dr. Plott served as Vice President, Clinical Research and
Regulatory Affairs and later Consulting Dermatologist at Medicis
Pharmaceutical Company, a specialty pharmaceutical company in
the United States focusing
primarily on the treatment of dermatological and aesthetic
conditions from 2001 through 2007. Prior to Medicis, Dr. Plott
served as a Director in Clinical Research at leading pharmaceutical
companies with emphasis in dermatology including Schering-Plough,
Galderma Laboratories and Dermik Laboratories. As a result of his
extensive experience, he was appointed to the FDA Dermatologic and
Ophthalmic Drug Advisory Committee. During his distinguished
career, Dr. Plott has monitored tens of thousands of patients and
hundreds of clinical trials. Dr. Plott returned to private practice
in 2011, where he currently serves as Chief Medical Officer for
Epiphany Dermatology based in Austin,
Texas.
"Dr. Plott's impressive experience will be invaluable to
BioPharmX as we progress through clinical research on our path to
FDA approval," said Dr. David
Tierney, BioPharmX CEO. "His deep knowledge of the
development and regulatory process will provide insight that will
help BioPharmX remain focused on our goal of offering
dermatologists and their patients new treatment options. We are
thrilled that he is joining our team."
"I am honored to join the BioPharmX board of directors, which
shares my passion for developing needed dermatology products," said
Dr. Plott. "BioPharmX is working on two investigational products
that may someday deliver efficacy and safety benefits over existing
therapeutic options. I look forward to contributing my expertise to
the BioPharmX team as we work together to improve patient
outcomes."
About BioPharmX Corporation
BioPharmX Corporation (NYSE American: BPMX) is a specialty
pharmaceutical company developing prescription products through its
proprietary HyantX™ Topical Delivery System for dermatology
indications. To learn more about BioPharmX,
visit www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. This press release
contains forward-looking statements about the company's
expectations, plans, intentions, and strategies, including, but not
limited to, the company's ability to complete clinical studies and
advance its product candidates through regulatory approval, to
commercialize its drug delivery program and to obtain patent
protection and defend its intellectual property. Additional risks
are set forth in our filings with the Securities and Exchange
Commission, including those described in the company's Quarterly
Report on Form 10-Q for the most recent fiscal quarter. The
forward-looking statements included in this news release are made
only as of the date hereof, and the company undertakes no
obligation to publicly update such statements. BioPharmX is a
registered trademark of BioPharmX, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biopharmx-strengthens-board-of-directors-with-appointment-of-industry-veteran-dr-r-todd-plott-300788433.html
SOURCE BioPharmX Corporation